{"id":1794,"date":"2024-03-20T17:52:29","date_gmt":"2024-03-20T17:52:29","guid":{"rendered":"https:\/\/stoxpo.com\/?p=1794"},"modified":"2024-03-20T17:52:30","modified_gmt":"2024-03-20T17:52:30","slug":"igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2024\/03\/20\/igc-pharmas-igc-ad1-shows-promising-results-in-alzheimers-agitation-trial\/","title":{"rendered":"IGC Pharma’s IGC-AD1 Shows Promising Results in Alzheimer’s Agitation Trial"},"content":{"rendered":"\n

Interim Analysis Reveals Statistically Significant Reduction in Agitation Levels<\/h4>\n\n\n\n

IGC Pharma (IGC) has unveiled encouraging findings from its ongoing Phase 2 trial of IGC-AD1 for Agitation in Dementia from Alzheimer\u2019s Disease (AAD). With Alzheimer’s affecting an estimated 6.7 million Americans in 2023, addressing agitation is crucial, as up to 76% of patients experience this symptom.<\/p>\n\n\n\n

The interim analysis showcases a notable reduction in agitation among Alzheimer’s patients treated with IGC-AD1 compared to those receiving a placebo. Using the Cohen Mansfield Agitation Inventory (CMAI) scale, patients exhibited significantly lower agitation scores as early as week two of the trial.<\/p>\n\n\n\n

Key findings include a Cohen\u2019s d effect size of 0.66 at the primary outcome assessment at week six, indicating the superiority of IGC-AD1 over placebo. Additionally, the LS mean difference between active and placebo was -10.45, with a p-value of 0.037.<\/p>\n\n\n\n

These promising results underscore the potential of IGC-AD1 to improve patient outcomes in Alzheimer’s-related agitation. Ram Mukunda, CEO of IGC Pharma, expressed confidence in the clinical profile of IGC-AD1, signaling its potential to drive shareholder value pending further trials.<\/p>\n\n\n\n

Read original press release:here<\/mark><\/a><\/p>\n\n\n\n

You might like this article:XTL Biopharmaceuticals Announces Acquisition of The Social Proxy: A Strategic Move in AI Data Extraction<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Interim Analysis Reveals Statistically Significant Reduction in Agitation Levels IGC Pharma (IGC) has unveiled encouraging findings from its ongoing Phase 2 trial of IGC-AD1 for Agitation in Dementia from Alzheimer\u2019s Disease (AAD). With Alzheimer’s affecting an estimated 6.7 million Americans in 2023, addressing agitation is crucial, as up to 76% of patients experience this symptom. […]<\/p>\n","protected":false},"author":1,"featured_media":1796,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"1","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"1","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]}},"categories":[358,309],"tags":[],"coauthors":[453],"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1794"}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=1794"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1794\/revisions"}],"predecessor-version":[{"id":1797,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1794\/revisions\/1797"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1796"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=1794"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=1794"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=1794"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=1794"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}